New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06970496
Summary
This is an early-stage study testing a new cell therapy called B019 injection in patients whose B-cell non-Hodgkin's lymphoma has returned or not responded to previous treatments. The main goals are to find a safe dose and see how well patients tolerate the treatment, while also checking for any early signs that it might help shrink tumors. The study will enroll about 48 adults who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangxi Cancer Hospital
Nanchang, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Contact
-
Shanghai General Hospital
Shanghai, China
Contact
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Contact
-
Xijing Hospital
Xi'an, China
Contact
-
Zhujiang Hospital of Southern Medical University
Guangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.